Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. While there are positive developments like new partnerships and strategic market expansion, financial metrics show increased losses and expenses. The Q&A highlights potential growth in DNase1 markets and new partnerships, but lacks specific financial guidance. Increased cash reserves provide some stability, yet the lack of detailed financial projections and increased operating losses offset the positives, leading to a neutral sentiment.
Key Financial Performance
Total Revenue $1.165 million, a decrease from $1.958 million year-over-year. The decrease was due to reductions in research and development revenue by $183,000 and license and milestone revenue by $1.425 million, offset by an increase in grant revenue of $815,000 from the Gates Foundation and CEPI grant.
Cost of Research and Development Revenue and Cost of Grant Revenue $255,000, a decrease from $396,000 year-over-year. Cost of grant revenue from the Gates Foundation and CEPI brands was $769,000 compared to $0 in the same period a year ago.
Research and Development Expenses $572,000, an increase from $460,000 year-over-year. The increase was driven by a rise in the number of active internal research initiatives to expedite product development.
General and Administrative (G&A) Expenses $1.481 million, an increase from $1.298 million year-over-year. The increase was due to rebranding and business development expenses of $176,000, legal and accounting expenses of $83,000, partially offset by a decrease in share-based compensation expenses of $79,000.
Loss from Operations $1.925 million, an increase from $203,000 year-over-year. This reflects higher operating expenses and reduced revenue.
Net Loss $1.976 million or $0.06 per share, an increase from $203,000 or $0.01 per share year-over-year. This was driven by increased operating expenses and reduced revenue.
Cash and Cash Equivalents $10.4 million as of September 30, 2025, an increase from $9.3 million as of December 31, 2024. This includes proceeds from a public offering and a milestone payment from Proliant.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
First commercial bulk sale of Dyadic-produced protein: Marked the beginning of a new chapter in the company's evolution, with momentum expected to build in 2025 and accelerate in 2026.
Recombinant human albumin program: Advancing toward commercial launch in early 2026 in partnership with Proliant Health and Biologicals, with $1.5 million in milestone payments received to date.
Recombinant bovine fibroblast growth factor (FGF): First bulk purchase order achieved, targeting cultured meat and cell and gene therapy markets.
Animal-free transferrin and DNase1: In active manufacturing and sampling, preparing for commercial launch.
Recombinant alpha-lactalbumin and human lactoferrin: Advancing in the food and nutrition market, with sampling expected by late 2025 or early 2026.
Partnership with Intralink: Expanding market penetration in Japan and South Korea for cell culture media and molecular biology reagents.
Food and nutrition market expansion: Targeting the animal-free dairy protein market, expected to exceed $20 billion by 2035.
Rebranding and technology enhancement: Rebranded as Dyadic Applied BioSolutions and added CRISPR/Cas9 gene editing capabilities to improve productivity and yields.
Collaboration with Fermbox Bio: Advancing enzyme solutions for industrial biotechnology, with initial commercial deliveries completed.
Shift to a commercially focused biotechnology company: Transitioned from a platform-centric R&D organization to a product company with growing revenue streams.
Biopharmaceutical collaborations: Partner-funded programs with Gates Foundation and CEPI to validate C1 protein production platform and generate nondilutive funding.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decrease: Total revenue for Q3 2025 decreased to $1.165 million from $1.958 million in Q3 2024, driven by declines in research and development revenue and license/milestone revenue. This could impact the company's ability to fund operations and strategic initiatives.
Increased Operating Loss: Loss from operations increased to $1.925 million in Q3 2025 compared to $203,000 in Q3 2024, reflecting higher expenses and reduced revenue, which could strain financial resources.
Net Loss Growth: Net loss for Q3 2025 rose to $1.976 million from $203,000 in Q3 2024, indicating financial challenges that may hinder future investments and growth.
Dependence on Partner Funding: The company relies on partner-funded collaborations and grants, such as those from the Gates Foundation and CEPI, which may not be sustainable or predictable long-term.
Market Entry Risks: The company is entering competitive markets like cell culture media, molecular biology reagents, and animal-free proteins, which require significant resources and may face challenges in achieving market penetration.
Regulatory and Scalability Challenges: Products like recombinant human albumin and other proteins must meet stringent regulatory standards and scalability requirements, posing risks to commercialization timelines.
Supply Chain and Manufacturing Risks: Scaling up production for products like DNase1 and transferrin involves risks related to supply chain reliability and manufacturing consistency.
Geographic Expansion Risks: Efforts to expand into Asia-Pacific markets through partnerships like Intralink may face cultural, regulatory, and logistical challenges.
R&D and Operational Costs: Increased R&D expenses and operational costs, including rebranding and business development, could pressure margins and delay profitability.
Economic and Competitive Pressures: The company operates in dynamic and competitive sectors like biotechnology and food nutrition, where economic uncertainties and competitive pressures could impact growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercial Bulk Sales: The company expects momentum to build with additional product opportunities emerging in 2025 and accelerating in 2026 as they scale their portfolio and expand global market reach.
Recombinant Human Albumin Program: The program is advancing toward commercial launch in early 2026, with expectations to share profits as albumin products enter the market.
Animal-Free Transferrin and DNase1: These products are in active manufacturing and sampling to prepare for commercial launch. Bovine transferrin targets cultivated meat and research markets, while human transferrin targets biopharmaceutical and cell and gene therapy applications.
FGF Program: The program is expanding sampling and validation activities with additional customers, targeting cell and gene therapy manufacturers and suppliers.
RNA-Free DNase1: Production validation is complete, and the product has entered sampling while the company works to secure purchase orders.
T7 RNA Polymerase and RNase Inhibitor: Development is advancing to expand Dyadic's position in the DNA and RNA enzyme market.
Asia-Pacific Market Expansion: The company has partnered with Intralink to accelerate market penetration in Japan and South Korea, introducing products such as transferrin, DNase1, and growth factors.
Food and Nutrition Market: The recombinant alpha-lactalbumin program is advancing, with sampling for research and nutritional applications expected by late 2025 or early 2026. The human lactoferrin program is progressing, with sampling for research use expected in early 2026.
Non-Animal Dairy Enzymes: Scale-up for the first enzyme remains on track for commercial launch in late 2025 or early 2026, with a second enzyme candidate advancing toward commercialization.
Bioindustrial Segment: Initial commercial deliveries have been completed, and sampling is expanding with additional customers in biomass processing, biofuels, and pulp and paper markets. Revenues are expected in the first half of 2026.
Biopharmaceutical Programs: Programs supported by the Gates Foundation and CEPI are generating strong data, with potential for additional funding and validation of the C1 platform. The company is preparing to provide H5 antigen samples for preclinical evaluation, with potential advancement into a funded Phase I trial.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What does the new relationship with ERS Genomics bring to the company's portfolio?
A:The license with ERS Genomics provides a more powerful genetic toolbox to accelerate product development, improve optimization yields, and offer a competitive advantage in markets like food and nutrition. It also helps expand and accelerate internal programs.
Q:How should the DNA 1 opportunity ramp up in 2026 and beyond, and how big could it become?
A:The DNase1 market is approximately $250 million for recombinant products and $1.5 billion overall. The company is targeting bulk sale opportunities through OEM agreements. Initial revenues will focus on lab-grade material, with plans to expand to higher-margin segments like ISO and GMP grades. Growth is expected to be steady, driven by opportunities in cell and gene therapy and other markets.
Q:What are the characteristics of customers targeted in Asia through the Intralink relationship?
A:The company is targeting cell and gene therapy manufacturers, suppliers, and distributors in Asia, particularly in Japan and Korea. These markets are experiencing significant growth, and the focus is on bulk purchase orders rather than wholesale distribution to academic institutions.
Q:Would tariffs apply to the company's products in Japan and Asia?
A:Tariffs would apply to products coming back to the U.S., not to the technology being transferred out. The company is leveraging its global footprint to mitigate tariff implications.
Q:How is the CRISPR ERS agreement structured financially?
A:The financial details are confidential, but the agreement involves modest upfront costs and potential royalties. The focus is on improving fungal cell lines for efficiency and quality, rather than human applications. The agreement provides advantages in time and specificity for cell manipulation.
Q:What is the goal of the infant nutrition product, and how will it be marketed?
A:The goal is to mimic human breast milk and bovine milk using recombinant proteins. These products offer better quality assurance and scalability compared to natural sources. They are expected to first appear in medical and sports nutrition before infant nutrition, with regulatory and consumer hurdles to overcome.
Q:What is the potential endgame for the Gates Foundation and CEPI grants?
A:The grants aim to save lives and provide financial rewards. They also validate the company's platform for biopharmaceutical use and open opportunities for cell culture media and therapeutic proteins.
Q:Are the three products (DNA, transferrin, growth factor) derisked for production validation, and is the CDMO market a bottleneck?
A:The products are derisked for production validation, and the CDMO market currently has sufficient capacity. The company is working with CDMOs globally to reduce tariff implications and improve distribution economics.
Q:What is the company's cash burn and ability to execute its plans?
A:The company does not provide specific cash guidance but expects operating expenses to align with the previous year. It received $0.5 million in cash from Proliant in Q4 and anticipates additional product revenue.
Q:How does the business model scale in terms of headcount and expenses?
A:The model focuses on distributors, wholesalers, and suppliers, requiring minimal infrastructure changes. G&A expenses are not expected to grow proportionally with revenue, allowing for operating leverage.
Q:Review of Unclear Management Responses
A:Management avoided providing specific financial details about the CRISPR ERS agreement, citing confidentiality. Additionally, they did not disclose exact cash burn figures or specific product revenue expectations, making it difficult to assess financial projections.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO update
Dapibus platform
FBS
Fondazione Biotecnopolo
Intralink
Life Sciences
Proliant
ability
animal protein
antigen
biology reagent
biotechnology
capability
cell gene
consistency
enzyme technology
expertise
funding
hub
input
lactalbumin program
manufacturer
market collaboration
market reach
material
meat market
product position
production validation
property
protein production
purity
reach technology
sampling
scale
story
strain optimization
supply chain
tissue
transformation
transition
DYAI Transcript
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Positive5-14
The company reported improved financial metrics, including a reduction in net loss and operating losses, along with a strong cash position. The Q&A highlighted steady growth prospects for recombinant bovine transferrin and potential vaccine development using C1 technology, both of which are positive indicators. The company has successful partnerships, like with Intralink and Phibro, and a promising market strategy focusing on cultured meat. Despite some unclear management responses, the overall sentiment leans positive, with no major negative indicators to suggest a downturn.
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Positive3-26
The earnings call summary shows strong financial performance with a 25% revenue increase and a 33% net income rise. Despite increased operating expenses, cash flow improved by 15%. The strategic initiatives and biopharmaceutical program updates were not detailed, but the financial results suggest positive market sentiment. The lack of specific shareholder return plans and operational updates slightly tempers the outlook, but the overall positive financial indicators and market expansion support a positive sentiment.
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Neutral12-9
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals mixed signals. While there are positive developments like new partnerships and strategic market expansion, financial metrics show increased losses and expenses. The Q&A highlights potential growth in DNase1 markets and new partnerships, but lacks specific financial guidance. Increased cash reserves provide some stability, yet the lack of detailed financial projections and increased operating losses offset the positives, leading to a neutral sentiment.
DYAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
